Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Pharmacological inhibition of the canonical Wnt/β-catenin signaling pathway sensitizes 5-fluorouracil-resistant colorectal cancer cells.

Created on 05 Sep 2026

Authors

Diego Alfonso Arregui Ramos, Daniela Filomena Tavares de Pina, Annie Cristhine Moraes Sousa-Squiavinato, Wallace Martins de Araújo, Murilo Ramos Rocha, Jose Andres Morgado-Diaz

Published in

Molecular biology reports. Volume 53. Issue 1. Sep 04, 2026. Epub Sep 04, 2026.

Abstract

The activation of the Wnt/β-catenin pathway with chemoresistance in colorectal cancer has been hypothesized. However, the use of specific inhibitors for targeting this pathway has not been well explored. In the present study, we analyze the activation of this pathway and its role in the stemness phenotype acquisition to regulate chemoresistance using our long-term 5-fluorouracil (5-FU) - resistant model of colorectal cancer cells, known to present epithelial-mesenchymal transition and enhanced migration and invasion.
Initially by bioinformatic analyses we demonstrate the association between 5-FU resistance genes with those of a stem cell-like phenotype in patients with colon cancer. In addition, 5-FU-resistant cells displayed stemness characteristics, with upregulation of key stem cell marker (ALDH1A1) using reverse transcription-quantitative polymerase chain reaction. Further, 5-FU-resistant cells exhibited high Wnt/β-catenin pathway activity. Interestingly, treatment with LF3, an inhibitor of this pathway, re-sensitized the 5-FU-resistant cells, decreasing their proliferation.
Wnt/β-catenin pathway activation plays a role in regulating key cellular events involved in chemoresistance. The study findings suggest the use of combinatorial therapies using conventional agents, such as 5-FU, and inhibitors of this pathway, as a useful therapeutic strategy to treat patients with colorectal cancer.

PMID:
42696229
Bibliographic data and abstract were imported from PubMed on 05 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement